SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $555 | -8.3% | 20,140 | 0.0% | 0.05% | -3.9% |
| Q2 2023 | $605 | -16.6% | 20,140 | +0.7% | 0.05% | -22.7% |
| Q1 2023 | $725 | +1.7% | 20,000 | 0.0% | 0.07% | -2.9% |
| Q4 2022 | $713 | -99.9% | 20,000 | 0.0% | 0.07% | -1.4% |
| Q3 2022 | $677,000 | +17.1% | 20,000 | 0.0% | 0.07% | +25.5% |
| Q2 2022 | $578,000 | -10.5% | 20,000 | 0.0% | 0.06% | +5.8% |
| Q1 2022 | $646,000 | +4.7% | 20,000 | -5.4% | 0.05% | +10.6% |
| Q4 2021 | $617,000 | -42.4% | 21,145 | -47.3% | 0.05% | -48.4% |
| Q3 2021 | $1,071,000 | +57.0% | 40,145 | +81.3% | 0.09% | +56.9% |
| Q2 2021 | $682,000 | +7.9% | 22,145 | -8.3% | 0.06% | -1.7% |
| Q1 2021 | $632,000 | +4.1% | 24,145 | 0.0% | 0.06% | 0.0% |
| Q4 2020 | $607,000 | +20.7% | 24,145 | 0.0% | 0.06% | +9.3% |
| Q3 2020 | $503,000 | -26.0% | 24,145 | -15.7% | 0.05% | -33.3% |
| Q2 2020 | $680,000 | +32.0% | 28,645 | 0.0% | 0.08% | +8.0% |
| Q1 2020 | $515,000 | -24.2% | 28,645 | 0.0% | 0.08% | -6.2% |
| Q4 2019 | $679,000 | -13.7% | 28,645 | 0.0% | 0.08% | -19.2% |
| Q3 2019 | $787,000 | -17.0% | 28,645 | 0.0% | 0.10% | -18.9% |
| Q2 2019 | $948,000 | -5.6% | 28,645 | 0.0% | 0.12% | -12.9% |
| Q1 2019 | $1,004,000 | +5.4% | 28,645 | -0.2% | 0.14% | -7.3% |
| Q4 2018 | $953,000 | -35.2% | 28,700 | -1.7% | 0.15% | -24.1% |
| Q3 2018 | $1,470,000 | -15.9% | 29,200 | 0.0% | 0.20% | -22.0% |
| Q2 2018 | $1,748,000 | +30.7% | 29,200 | 0.0% | 0.26% | +27.5% |
| Q1 2018 | $1,337,000 | +14.9% | 29,200 | 0.0% | 0.20% | +14.9% |
| Q4 2017 | $1,164,000 | -1.0% | 29,200 | -0.7% | 0.17% | -9.8% |
| Q3 2017 | $1,176,000 | -7.2% | 29,400 | 0.0% | 0.19% | -11.1% |
| Q2 2017 | $1,267,000 | +30.6% | 29,400 | -5.2% | 0.22% | +26.9% |
| Q1 2017 | $970,000 | -58.7% | 31,000 | -66.7% | 0.17% | -58.7% |
| Q4 2016 | $2,348,000 | +2.1% | 93,000 | 0.0% | 0.41% | -1.0% |
| Q3 2016 | $2,300,000 | +6.1% | 93,000 | -12.6% | 0.42% | +1.7% |
| Q2 2016 | $2,167,000 | +24.0% | 106,375 | -7.2% | 0.41% | +19.1% |
| Q1 2016 | $1,747,000 | +4.3% | 114,575 | -8.1% | 0.34% | +4.9% |
| Q4 2015 | $1,675,000 | -10.3% | 124,650 | -6.3% | 0.33% | -11.1% |
| Q3 2015 | $1,867,000 | -30.7% | 133,075 | -16.2% | 0.37% | -23.4% |
| Q2 2015 | $2,696,000 | +52.4% | 158,775 | +8.5% | 0.48% | +49.1% |
| Q1 2015 | $1,769,000 | +12.8% | 146,325 | -22.6% | 0.32% | +8.7% |
| Q4 2014 | $1,568,000 | -19.1% | 188,975 | -15.3% | 0.30% | -19.2% |
| Q3 2014 | $1,939,000 | -18.2% | 223,075 | +3.1% | 0.37% | -18.5% |
| Q2 2014 | $2,369,000 | +10.4% | 216,350 | -9.8% | 0.45% | +5.3% |
| Q1 2014 | $2,145,000 | +36.5% | 239,900 | +15.1% | 0.43% | +35.2% |
| Q4 2013 | $1,572,000 | +22.3% | 208,450 | +19.0% | 0.32% | +10.4% |
| Q3 2013 | $1,285,000 | +72.9% | 175,200 | +51.7% | 0.29% | +58.2% |
| Q2 2013 | $743,000 | – | 115,500 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |